Invention Grant
- Patent Title: Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof
-
Application No.: US16764788Application Date: 2018-11-06
-
Publication No.: US11667704B2Publication Date: 2023-06-06
- Inventor: Pinliang Hu , Jing Zou , Weidong Hong , Yun He , Jie Bai , Lingyun Song , Wendi Yang , Zhijian Lv , Shaoyun Xiang
- Applicant: BEIJING BEYOND BIOTECHNOLOGY CO., LTD , HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
- Applicant Address: CN Beijing
- Assignee: BEIJING BEYOND BIOTECHNOLOGY CO., LTD,HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
- Current Assignee: BEIJING BEYOND BIOTECHNOLOGY CO., LTD,HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
- Current Assignee Address: CN Beijing; CN Hangzhou
- Agency: Hoxie & Associates LLC
- Priority: CN 1711137039.8 2017.11.16
- International Application: PCT/CN2018/114079 2018.11.06
- International Announcement: WO2019/096026A 2019.05.23
- Date entered country: 2020-05-15
- Main IPC: C07K16/46
- IPC: C07K16/46 ; C07K14/00 ; A61K39/00 ; C12N15/00 ; C07K16/24 ; A61P29/00 ; C12N15/52
Abstract:
The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
Public/Granted literature
- US20210261654A1 ANTI-IL-17 ANTIBODY/TNFR ECD FUSION PROTEIN AND USE THEREOF Public/Granted day:2021-08-26
Information query
